Achieving the key objectives of the Molecular Pathology Node will generate world-class facilities and expertise in Newcastle and the role of the Translation and Industry group is to engage with partners to improve patient outcomes through the application of our state of the art pathology techniques and the development of new tools. This will then lead to a more rapid adoption of new technology to the NHS.
In addition to responding to the needs of industry, the activity within the Node is expected to lead to innovation in techniques and identification of potential biomarkers and diagnostic tools. The Node is looking to work closely with partners to translate that intellectual property, to access support for investment, product development, validation and market analysis. And in so doing will maximize the opportunity to generate value that can be re-invested in research activity.